Anthera Pharmaceuticals (NASDAQ:ANTH) was downgraded by equities research analysts at Piper Jaffray Companies from an “overweight” rating to an “underweight” rating in a note issued to investors on Monday.

Several other analysts have also recently commented on ANTH. ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research report on Monday, January 8th. Roth Capital initiated coverage on Anthera Pharmaceuticals in a research report on Wednesday, February 21st. They set a “buy” rating and a $10.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of Anthera Pharmaceuticals in a research report on Tuesday, March 6th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Anthera Pharmaceuticals has a consensus rating of “Hold” and an average price target of $4.38.

Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) opened at $0.48 on Monday. Anthera Pharmaceuticals has a 12-month low of $0.40 and a 12-month high of $3.84. The company has a market capitalization of $1.28, a P/E ratio of -0.15 and a beta of 2.22.

Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its quarterly earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.82) by $0.09. analysts expect that Anthera Pharmaceuticals will post -1.75 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANTH. Armistice Capital LLC acquired a new position in Anthera Pharmaceuticals during the fourth quarter worth $1,269,000. 683 Capital Management LLC acquired a new position in Anthera Pharmaceuticals during the fourth quarter worth $399,000. Finally, BVF Inc. IL boosted its stake in Anthera Pharmaceuticals by 20.9% during the fourth quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock worth $2,007,000 after buying an additional 209,896 shares during the last quarter. 28.12% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with's FREE daily email newsletter.